publication venue for
- Do nonglycaemic effects such as weight loss account for HbA1c lowering with efpeglenatide?: Insights from the AMPLITUDE-O trial.. 26:6080-6084. 2024
- Body weight variability as a predictor of cardiovascular outcomes in type 1 diabetes: A nationwide cohort study. 2024
- Evaluating remission of type 2 diabetes using a metabolic intervention including fixed-ratio insulin degludec and liraglutide: A randomized controlled trial.. 26. 2024
-
Determinants of serious health
outcome‐free status inmiddle‐aged and older people with dysglycaemia: Exploratory analysis of theORIGIN trial. 26:3272-3280. 2024 - Development and first‐stage validation of a digital version of the Digit Symbol Substitution test for use in assessing cognitive function in older people with diabetes. 26:3299-3305. 2024
- Cardiovascular and renal outcomes with varying degrees of kidney disease in high‐risk people with type 2 diabetes: An epidemiological analysis of data from the AMPLITUDE‐O trial. 26:1216-1223. 2024
-
Effect of basal insulin and omega 3 fatty acids on cognitive impairment in dysglycaemia: An exploratory analysis of the
ORIGIN trial. 26:1180-1187. 2024 -
S odium‐glucose co‐transporter‐2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes. 26:699-709. 2024 - Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial. 25:3347-3355. 2023
-
Oral anticoagulation across diabetic subtypes in patients with newly diagnosed atrial fibrillation: A report from the
GARFIELD‐AF registry. 25:3040-3053. 2023 -
Effect of lixisenatide on natriuretic peptides in people with type 2 diabetes and recent acute coronary syndrome: The
ELIXA trial. 25:1125-1129. 2023 -
Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to
iGlarLixi in theLixiLan ONE CAN randomized trial. 24:1998-2007. 2022 -
Efficacy and safety outcomes of dulaglutide by baseline
HbA1c : A post hoc analysis of theREWIND trial. 24:1753-1761. 2022 -
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the
REWIND randomized trial. 24:704-712. 2022 -
Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes (
RESET‐IT Main ): A 2‐year randomized controlled trial. 23:1926-1935. 2021 -
Design and baseline characteristics of the
AMPLITUDE‐O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon‐like peptide‐1 receptor agonist. 23:318-323. 2021 - Effects of basal insulin glargine and omega‐3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INtervention (ORIGIN) trial. 21:1502-1505. 2019
- Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. 21:1299-1304. 2019
- The effects of incretin‐based therapies on β‐cell function and insulin resistance in type 2 diabetes: A systematic review and network meta‐analysis combining 360 trials. 21:975-983. 2019
- Association between diabetic eye disease and other complications of diabetes: Implications for care. A systematic review. 21:467-478. 2019
- The association of basal insulin treatment versus standard care with outcomes in anti‐GAD positive and negative subjects: A post‐hoc analysis of the ORIGIN trial. 21:429-433. 2019
- Adjusting insulin doses in patients with type 1 diabetes who use insulin pump and continuous glucose monitoring: Variations among countries and physicians. 20:2458-2466. 2018
- Clinical correlates of hypoglycaemia over 4 years in people with type 2 diabetes starting insulin: An analysis from the CREDIT study. 20:921-929. 2018
-
Insulin resistance and cardiovascular outcomes in the
ORIGIN trial. 20:564-570. 2018 - Metformin for the management of peri‐operative hyperglycaemia. 20:753-754. 2018
-
Design and baseline characteristics of participants in the
R esearching cardiovascularE vents with aW eeklyIN cretin inD iabetes (REWIND ) trial on the cardiovascular effects of dulaglutide. 20:42-49. 2018 - Scriptaid enhances skeletal muscle insulin action and cardiac function in obese mice. 19:936-943. 2017
-
Metformin in adults with type 1 diabetes:
D esign and methods ofREducing withMetfOrmin V ascularA dverseL esions (REMOVAL ):A n international multicentre trial. 19:509-516. 2017 -
Cardiovascular events and all‐cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs:
A B ayesian meta‐analysis of survival data. 19:329-335. 2017 - Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004–2013. 18:607-614. 2016
- Patient Empowerment Programme in primary care reduced all‐cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population‐based propensity‐matched cohort study. 17:128-135. 2015
- A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. 15:1093-1100. 2013
- Acute high‐intensity interval exercise reduces the postprandial glucose response and prevalence of hyperglycaemia in patients with type 2 diabetes. 14:575-577. 2012
- Interleukin‐15 treatment improves glucose homeostasis and insulin sensitivity in obese mice. 14:190-193. 2012
- Rosiglitazone prevents diabetes by increasing beta‐cell mass in an animal model of type 2 diabetes characterized by reduced beta‐cell mass at birth. 10:763-771. 2008
- Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. 8:531-537. 2006
- Preventing type 2 diabetes using combination therapy: design and methods of the CAnadian Normoglycaemia Outcomes Evaluation (CANOE) trial. 8:531-537. 2006
- Trauma & the reproductive lifecycle in women. 7:S65-S72. 2005
- Women's mental health: what don't we know?. 7:S41-S42. 2005